Q&A Panel Discussion: Overcoming Toxicity & Immunogenicity Challenges
Time: 9:25 am
day: Day Two
Details:
• Does it depend on the disorder?
• What are best preclinical models for toxicology risk assessment?
• Reviewing preclinical data for CNS and systemic toxicity
• How does this translate into humans?
• Discussing immunogenicity concerns for patients
